Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma.
The extrapulmonary effects of slow-release theophylline and an inhaled beta 2-agonist (albuterol) were examined separately and in combination among 18 adults and adolescents with asthma during a 3-month randomized, double-blind, crossover trial. Although neither global impressions nor daily diaries revealed differences in adverse effects, a structured questionnaire completed at the end of each regimen suggested a small but statistically significant increase in nausea and depressive and caffeine-like symptoms during the theophylline-containing regimens. Theophylline was also associated with improved verbal learning but decreased motor steadiness. Metabolic effects associated with theophylline included lower serum bicarbonate, greater urinary calcium excretion, and higher serum calcium, uric acid, and creatinine. Albuterol was associated with lower neutrophil counts and lower serum theophylline concentrations. There were no drug-induced effects on cardiac rhythm.
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001639:Bicarbonates / Q000097:blood; D002118:Calcium / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D006321:Heart / Q000187:drug effects; D006323:Heart Arrest / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009484:Neuropsychology; D010349:Patient Compliance; D013806:Theophylline / Q000009:adverse effects / Q000627:therapeutic use*
D001639:Bicarbonates; D003404:Creatinine; D013806:Theophylline; D000420:Albuterol; D002118:Calcium